Medicare AdvantagePrior AuthMedium impact
MA08.149a, Inclisiran (Leqvio®)
Independence Blue Cross·Cardiology, Endocrinology, Internal Medicine·Pharmacy
Effective date
Oct 1, 2025
We identified it
Jun 19, 2026
Summary
MA08.149a updates Medicare Advantage coverage policy for Inclisiran (Leqvio®), a PCSK9 inhibitor used for hypercholesterolemia management. This recent policy (effective 10/01/2025) establishes new or modified coverage criteria, prior authorization requirements, and/or billing guidelines for this pharmacy benefit. Billing teams must review specific coverage restrictions and authorization workflows to ensure compliant claim submission.
Action Required
By October 1, 2025: Billing and clinical staff must obtain the complete MA08.149a policy text from the source URL to identify: (1) prior authorization requirements for Inclisiran claims, (2) specific coverage criteria and medical necessity documentation needed, (3) any applicable HCPCS J-codes for the drug administration. Update billing system workflows, prior auth submission templates, and provider communication materials accordingly. Communicate requirements to cardiology, internal medicine, and endocrinology providers who prescribe this medication. Without proper prior authorization and documentation, claims will be denied.